People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally
believed that their long‐term use is harmful for patients' physical well‐being. However, there …

The goal of this guideline is to improve the quality of care and treatment outcomes for
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …

Background An oral compound, SEP-363856, that does not act on dopamine D2 receptors
but has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5 …

The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Objective To assess the employment rate and the related background factors among people
with schizophrenia or bipolar disorder. Methods We identified all people in Sweden aged 18 …

Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …